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Abstract
The cannabis constituent cannabidiol (CBD) possesses anxiolytic and antipsychotic properties. We have previously shown
that transmembrane domain neuregulin 1 mutant (Nrg1 TM HET) mice display altered neurobehavioural responses to the
main psychoactive constituent of cannabis, D
9-tetrahydrocannabinol. Here we investigated whether Nrg1 TM HET mice
respond differently to CBD and whether CBD reverses schizophrenia-related phenotypes expressed by these mice. Adult
male Nrg1 TM HET and wild type-like littermates (WT) received vehicle or CBD (1, 50 or 100 mg/kg i.p.) for 21 days. During
treatment and 48 h after withdrawal we measured behaviour, whole blood CBD concentrations and autoradiographic
receptor binding. Nrg1 HET mice displayed locomotor hyperactivity, PPI deficits and reduced 5-HT2A receptor binding
density in the substantia nigra, but these phenotypes were not reversed by CBD. However, long-term CBD (50 and 100 mg/
kg) selectively enhanced social interaction in Nrg1 TM HET mice. Furthermore, acute CBD (100 mg/kg) selectively increased
PPI in Nrg1 TM HET mice, although tolerance to this effect was manifest upon repeated CBD administration. Long-term CBD
(50 mg/kg) also selectively increased GABAA receptor binding in the granular retrosplenial cortex in Nrg1 TM HET mice and
reduced 5-HT2A binding in the substantia nigra in WT mice. Nrg1 appears necessary for CBD-induced anxiolysis since only
WT mice developed decreased anxiety-related behaviour with repeated CBD treatment. Altered pharmacokinetics in mutant
mice could not explain our findings since no genotype differences existed in CBD blood concentrations. Here we
demonstrate that Nrg1 modulates acute and long-term neurobehavioural effects of CBD, which does not reverse the
schizophrenia-relevant phenotypes.
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Introduction
Cannabis abuse is linked with a moderate increase in the risk of
developing schizophrenia [1] although this relationship has been
discussed controversially in the field [2–5]. The association of a
catechol-O-methyltransferase gene polymorphism with increased
psychotic symptom occurrence after adolescent cannabis use [6]
suggests that the extent and nature of the schizophrenia-relevant
behavioural effects of cannabis may have a genetic underpinning.
D
9-tetrahydrocannabinol (THC) is the most abundant of the .70
cannabis constituents and is responsible for the euphoric and
psychotomimetic effects of cannabis. Cannabidiol (CBD) is
another major cannabis constituent present in lower abundance
than THC in most cannabis samples [7] that is not psychotropic
and ameliorates some of the unpleasant psychoactive effects of
THC [8,9]. Therapeutic potential for CBD in treating psychiatric
disorders is suggested by reports of its antidepressant [10,11],
anxiolytic- [12,13] and antipsychotic-like effects [12–16] in rodent
models. CBD also produces anxiolytic effects in healthy volunteers
and those suffering from social anxiety disorders [17–19] and some
antipsychotic-like effects in schizophrenia patients [20]. While the
actions of CBD are not fully understood, it has a multitude of
pharmacological effects such as antagonising the effects of
cannabinoid receptor agonists [21,22], behaving as an inverse
agonist at cannabinoid CB2 receptors [22], blocking the orphan
receptor GPR55 [23], inhibiting fatty acid amide hydrolase, and
activating transient receptor potential vanilloid type 1 channels
[24].
We have investigated the effects of cannabis constituents in the
transmembrane domain neuregulin 1 heterozygous mutant (Nrg1
TM HET) mouse, a model for a schizophrenia susceptibility gene
that offers partial construct, predictive and face validity for
schizophrenia. These mice show age-dependent locomotor and
exploratory hyperactivity [25] [reversible with clozapine [26]],
impaired preference for social novelty [27] and cognitive deficits
(e.g. contextual fear conditioning [28]). Furthermore, Nrg1 TM
HET mice show altered susceptibility to the neurobehavioural
effects of THC [29–32]. Here, we aimed to assess the effect of
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We hypothesised that CBD treatment would attenuate the
hyperlocomotor activity of Nrg1 mutant mice, which is relevant
to the psychomotor agitation observed in the ‘positive’ signs of
schizophrenia [33]. Furthermore, we hypothesised that mutant
and wild type-like (WT) controls would show differential sensitivity
to CBD in a battery of tests relevant to schizophrenia [33] and that
these behavioural effects would be accompanied by changes in
receptor binding density of neurotransmitter systems known to be
involved in these behavioural domains. Our study demonstrates
that Nrg1 modulates acute and long-term neurobehavioural effects
of CBD, which does not reverse the schizophrenia-relevant
phenotypes.
Results
At the start of the study Nrg1 TM HET mice weighed
significantly less than their WT littermates [Nrg1 TM
HET=27.460.3 g versus WT=28.560.2 g; t(1,125)=3.1,
P,0.01] and this difference continued throughout the testing
period. Importantly, there was no effect of CBD treatment on
body weight development (data not shown). Also, there were no
overt signs of CBD treatment, such as on general home cage
activity levels, responsiveness to touch or piloerection.
Behavioural effects of acute CBD exposure
Locomotion and exploration. The well-established
hyperlocomotor phenotype of Nrg1 mutant mice was evident on
the first test day as measured in the OF [day 1: F(1,117)=11.3,
P=0.001; Fig. 1A]. Further analyses for the different treatment
groups revealed that this increase in motor activity of mutant mice
was only significant in animals treated with 1 mg/kg CBD, not in
those treated with 50 or 100 mg/kg CBD (Fig. 1A). However,
there was no significant genotype by treatment interaction. Nrg1
TM HET mice were also more explorative (i.e. vertical activity)
than their WT littermates in the OF [day 1: F(1,114)=7.6,
P,0.01; three mice excluded due to equipment malfunction;
Fig. 1B]. More specifically, OF exploration of mutant mice was
significantly increased in animals treated with an acute dose of
50 mg/kg CBD (Fig. 1D).
Anxiety. Anxiety parameters investigated in the OF (i.e. time
spent in the centre and distance ratio) on day 1 were similar for
both genotypes and were not affected by CBD treatment
(Fig. 2A+D). However, as published previously, Nrg1 TM HET
mice displayed an anxiolytic-like phenotype in the LD test
(Fig. 3A+D). Time spent in the light compartment of the LD
test was elevated in mutant mice on day 1 [F(1,117)=9.0, P,0.01]
compared with control mice. This anxiolytic-like phenotype was
statistically confirmed for vehicle-treated mutants and mutants
treated with 100 mg/kg CBD (Fig. 3A). Furthermore, Nrg1 mutant
mice displayed an increase in distance ratio in the more aversive
light compartment on test day 1 [F(1,115)=6.6, P,0.05; two
animals excluded due to equipment malfunction; Fig. 3D]. This
genotype difference was only significant in the group of animals
being treated with the highest dose of CBD (Fig. 3D). CBD had no
impact on anxiety-related measures of the LD test across
genotypes.
Sensorimotor gating. CBD treatment increased the mean
startle response on day 1 [F(3,113)=11.1, P,0.001]. This effect of
CBD was evident at a dose of 100 mg/kg in both genotypes
(Table 1). As expected, three-way RM ANOVA for ‘prepulse
intensity’ confirmed that % PPI increased with increasing prepulse
intensity on day 1 [F(2,226)=432.8, P,0.001; Fig. 4A]. Acute
CBD had a stimulating effect on % PPI of mice [F(3,113)=4.7,
P,0.01]. Specifically, CBD 100 mg/kg increased PPI in Nrg1 TM
HET mice at the 86 dB prepulse intensity compared with vehicle-
treated mutant mice (Fig. 4A).
Behavioural effects of long-term CBD exposure
Locomotion and exploration. Hyperlocomotion of Nrg1
mutant mice was evident on test day 13 [F(1,114)=18.3, P,0.001;
Fig. 1B]. This genotype effect was significant in animals treated
with vehicle or 1 mg/kg CBD but not in those treated with 50 or
100 mg/kg CBD (Fig. 1B). No interactions were detected.
Furthermore, mutant mice exhibited an overall explorative-like
phenotype in the OF [F(1,111)=9.3, P,0.01; three mice excluded
due to equipment malfunction], although this increase in
exploration failed to reach significance in any particular
treatment group (Fig. 1E).
Anxiety. CBD developed an anxiolytic-like effect in WT mice
by day 13 [F(3,114)=3.6, P,0.05], as indicated by an increase in
OF distance ratio for the 1 mg/kg and 100 mg/kg treatment
groups (Fig. 2E). No genotype-dependent effects were observed in
the OF on this test day. Nrg1 mutant mice displayed an increase in
distance ratio in the more aversive light compartment of the LD
test on test day 15 [F(1,103)=7.5, P,0.05; eleven mice excluded
due to equipment malfunction] but only in those mutant mice that
had been treated with 100 mg/kg CBD (Fig. 3E). CBD had no
impact on anxiety-related measures of the LD test across
genotypes.
Social interaction. Social interaction data are presented in
Table 2. Overall, CBD treatment increased social interaction as
measured by total duration of active social interaction
[F(3,112)=4.7, P,0.01]. Furthermore, CBD had a stimulating
effect on particular socio-positive behaviours in animals: nosing
[duration: F(3,112)=3.6, P,0.05] and anogenital sniffing
[frequency: F(3,112)=3.7, P,0.05 - duration: F(3,112)=6.2,
P=0.001]. Treatment with 50 mg/kg CBD selectively increased
total active social interaction time, nosing (duration and frequency)
and anogenital sniffing frequency in Nrg1 TM HETs. Importantly,
CBD at a dose of 50 mg/kg had no concomitant effect on
locomotor activity (data not shown). Furthermore, 100 mg/kg
CBD increased the duration of anogenital sniffing in mutant mice.
Finally, Nrg1 TM HET mice displayed increased frequencies of
nosing [F(1,112)=7.7, P,0.01]. This genotype effect was
significant in mutant animals treated with 1 mg/kg and 50 mg/
kg CBD.
Sensorimotor gating. Our analysis did not reveal any
significant effects of treatment or genotype on sensorimotor
gating. As expected, % PPI increased with increasing prepulse
intensity [day 21: F(2,220)=532.9, P,0.001; Fig. 4B].
Behavioural effects of withholding CBD for 48 h
None of the test mice showed any drug withdrawal-like
symptoms (e.g. wet dog shakes [34]) during OF, LD or PPI
testing 48 h post final CBD treatment.
Locomotion and exploration. The hyperlocomotor
phenotype of Nrg1 mutants was still detectable in the OF on the
last experimental day [WH day: F (1,112)=16.7, P,0.001]. This
increase in motor activity was significant for mutant mice of the
vehicle or 1 mg/kg CBD treatment groups (Fig. 1C). No
significant genotype by treatment interaction was found. Despite
an overall effect of genotype on exploration [WH day:
F(1,105)=7.6, P,0.01; seven mice excluded due to equipment
malfunction], only vehicle-treated Nrg1 HET mice showed a
significantly increased frequency of vertical activity compared to
WT mice in the OF (Fig. 1F).
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in distance ratio in the OF) compared with their WT littermates
on WH day [F(1,112)=8.9, P,0.01]. This phenotype was only
significantly different between vehicle-treated animals of both
genotypes (Fig. 2F). This finding was confirmed in the LD test
(Fig. 3). Time spent in the light compartment of the LD test was
Figure 1. Horizontal locomotor and vertical activity (i.e. rearing) in the open field test (10 min) after injection of CBD. A–C: Overall
distance travelled and D–F: Rearing on days 1, 13 and treatment withheld (WH) day. Data represent mean+S.E.M. Significant one-way ANOVA (split by
‘treatment’) results are shown: * P,0.05, ** P,0.01 (vs. WT receiving corresponding treatment).
doi:10.1371/journal.pone.0034129.g001
Figure 2. Anxiety-related measures in the open field test (10 min) after injection of CBD. A–C: Time spent in the central area and D–F:
Distance ratio on days 1, 13 and treatment withheld (WH) day. Data represent mean+S.E.M. Significant one-way ANOVA (split by corresponding
factor) results are shown: # P,0.05 (vs. vehicle of corresponding genotype). ** P,0.01 (vs. WT receiving corresponding treatment).
doi:10.1371/journal.pone.0034129.g002
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compared with control mice. This anxiolytic-like phenotype was
statistically confirmed for mutants treated with 100 mg/kg CBD
(Fig. 3C). In addition, Nrg1 mutant mice exhibited higher levels of
distance ratio in the light chamber of the LD test on WH day
[F(1,109)=4.8, P,0.05; three mice excluded due to equipment
malfunction]. This genotype difference was only significant in the
group of animals being treated with the highest dose of CBD
(Fig. 3F). CBD had no impact on anxiety-related measures of the
LD test across genotypes.
Sensorimotor gating. We detected significant differences
between the ASR of WT and Nrg1 mutant mice on WH day
[F(1,111)=8.3, P,0.01]. The startle response was reduced in Nrg1
TM HET mice treated with 1 mg/kg or 50 mg/kg CBD
compared with the corresponding WT groups (Table 1). As on
the other test days, % PPI was dependent on the prepulse intensity
[WH day: F(2,222)=498.6, P,0.001; Fig. 4C]. Importantly, our
analyses detected a PPI deficit in mutant mice on WH day
[F(1,111)=4.8, P,0.05], as % PPI was reduced in vehicle-treated
Nrg1 HET mice compared with WT controls at prepulse intensities
of 82 dB and 86 dB (Fig. 4C).
CBD concentration in whole blood
GC-MS analysis of CBD in whole blood obtained from Nrg1
TM HET and WT mice immediately after the final behavioural
test, performed 48 h after treatment cessation (48 h after the final
of 21 CBD injections: WH day), is depicted in Figure 5. There was
no difference between mutant and WT mice in CBD blood
concentration, which increased in a dose-dependent manner in
both genotypes [F(2,26)=11.5, P,0.001].
Effects of CBD on autoradiographic receptor binding
Representative autoradiograms for [
3H]ketanserin and
[
3H]muscimol binding in WT and Nrg1 TM HET mice are
depicted in Figure 6, and receptor binding data for all radioligands
Figure 3. Anxiety-related measures in the light-dark test (10 min) after injection of CBD. A–C: Time spent in the light compartment and
D–F: Distance ratio on days 1, 15 and treatment withheld (WH) day. Data represent means+S.E.M. Significant one-way ANOVA (split by ‘treatment’)
results are shown: * P,0.05, ** P,0.01 (vs. WT receiving corresponding treatment).
doi:10.1371/journal.pone.0034129.g003
Table 1. Startle response.
Day WT Nrg1 TM HET
Vehicle CBD 1 CBD 50 CBD 100 Vehicle CBD 1 CBD 50 CBD 100
1 48.864.9 56.067.7 51.864.9 81.266.8 ## 46.866.0 37.363.2 57.2610.0 78.868.2 ##
21 44.463.5 50.964.9 56.265.3 59.766.3 50.367.0 43.564.4 45.465.8 59.067.9
WH 52.864.1 54.265.3 50.865.4 46.363.9 47.267.3 39.763.6 * 34.964.7 * 40.465.9
Acute CBD (100 mg/kg) increases startle response [arbitrary units] to a 120 dB acoustic stimulus. Data represent means (6 S.E.M.). Significant one-way ANOVA (split by
corresponding factor) results are shown:
*P,0.05 (vs. WT receiving corresponding treatment);
##P,0.01 (vs. vehicle of corresponding genotype).
doi:10.1371/journal.pone.0034129.t001
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no changes in CB1, 5-HT1A or NMDAR radioligand binding in
any brain region (Table 3).
5-HT2A binding in the substantia nigra was reduced in Nrg1 TM
HET mice compared with WT and this effect was dose-
dependent, as confirmed by an interaction of ‘genotype’ with
‘treatment’ [F(3,30)=2.9, P,0.05]. Vehicle-treated Nrg1 mutants
had lower levels of 5-HT2A binding than WT animals.
Furthermore, 50 mg/kg CBD decreased specifically 5-HT2A
binding in WT mice with no such effect observed in mutant mice
(Table 3). There were no changes in 5-HT2A receptor binding in
any other region.
GABAA receptor binding was similar across genotypes.
However, a significant interaction of ‘genotype’ with ‘treatment’
for the granular retrosplenial cortex indicated, that treatment with
50 mg/kg CBD selectively increased GABAA receptor binding in
Nrg1 TM HET mice compared with vehicle controls [interaction:
F(3,31)=3.0, P,0.05]. There were no CBD-induced changes in
GABAA receptor binding in any other region (Table 3).
Discussion
Here we report a range of behavioural effects of acute and
chronic CBD in wild type-like and Nrg1 TM HET mice. CBD had
no effect on locomotor activity, although the typical hyperloco-
motive phenotype of Nrg1 TM HET mutant mice was not present
after long-term treatment and withholding of CBD (50 and
100 mg/kg). CBD selectively exerted anxiolytic-like effects in WT
mice in the OF at both low (1 mg/kg) and high (100 mg/kg) doses.
In contrast, high doses of CBD (50 and 100 mg/kg) selectively
increased social interaction in Nrg1 TM HET mice. Acute
administration of high-dose CBD enhanced PPI, but tolerance
to this effect occurred such that PPI was no longer altered
following chronic CBD. Nrg1 TM HET mice showed decreased 5-
HT2A binding in the substantia nigra. CBD did not reverse this
change, but enhanced 5-HT2A binding in the substantia nigra in
WT mice and increased GABAA density in Nrg1 TM HET mice.
Behavioural effects of Nrg1 genotype and CBD treatment
Locomotion and exploration. The lack of effects of acute or
long-term CBD on locomotor or exploratory activity is consistent
with its negligible motor effects reported for C57BL/6JArc mice,
the same inbred mouse strain used as the background for our Nrg1
model [14]. Baseline locomotor hyperactivity and moderately
increased exploratory activity in the OF were evident in Nrg1 TM
HET mice on all three test days, as observed previously
[25,29,31]. This hyperactivity was retained in Nrg1 TM HET
mice treated with the lower dose of CBD (1 mg/kg), but Nrg1 TM
HET mice treated with 50 and 100 mg/kg CBD did not express
either locomotor hyperactivity nor increased rearing. Notably, this
absence of hyperactivity persisted 48 h after cessation of CBD
treatment. Repeated treatment with higher doses of CBD might
reduce the potential for the hyperlocomotor phenotype to emerge,
which would be in line with reports that acute CBD prevents
hyperactivity induced by pharmacological agents such as
dexamphetamine [13,14]. Unfortunately, the response of Nrg1
Table 2. Social interaction.
Parameter WT Nrg1 TM HET
Vehicle CBD 1 CBD 50 CBD 100 Vehicle CBD 1 CBD 50 CBD 100
Nosing [n] 40.762.4 41.562.4 42.463.2 46.162.5 43.462.9 50.263.7 * 52.063.5 * 48.263.2
Nosing duration [s] 46.662.0 44.964.1 47.863.2 55.265.1 41.562.7 45.363.1 62.466.0 ## 51.665.8
Anogenital sniffing [n] 21.161.7 18.562.2 21.562.3 25.262.8 17.862.0 21.362.8 29.462.6 ## 26.263.4
Anogenital sniffing duration [s] 20.362.1 19.062.8 23.463.3 27.263.1 14.461.9 19.363.1 29.963.6 ## 23.361.9 ##
Total social interaction duration [s] 74.465.5 67.166.4 76.766.8 86.667.6 60.264.1 67.066.1 98.8610.3 ## 84.8610.3
Frequency and duration of nosing and anogenital sniffing with a standard opponent A/JArc mouse after injection with CBD (1, 50 or 100 mg/kg). Data represent means
(6 S.E.M.). Significant one-way ANOVA (split by corresponding factor) results are shown:
*P,0.05 (vs. WT receiving corresponding treatment);
##P,0.01 (vs. vehicle of corresponding genotype).
doi:10.1371/journal.pone.0034129.t002
Figure 4. Sensorimotor gating after injection of CBD. A–C: % PPI on days 1, 21 and treatment withheld (WH) day. Data represent means+S.E.M.
Significant one-way ANOVA (split by corresponding factor) results are shown: ## P,0.01 (vs. vehicle of corresponding genotype), * P,0.05,
** P,0.01 (vs. WT receiving corresponding treatment).
doi:10.1371/journal.pone.0034129.g004
Effects of Cannabidiol in Nrg1 Mutant Mice
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34129TM HET mice to chronic treatment with antipsychotics has not
been investigated and the behavioural response of mutant mice to
an acute dose of clozapine was task-dependent (i.e. reversal of OF
hyperlocomotion but not sensorimotor gating deficits [26]).
Anxiety. Vehicle-treated Nrg1 TM HET mice showed
reduced anxiety-like behaviour on test day 1 in the LD test and
on the last test day in the OF paradigm. Furthermore, Nrg1
mutants, who had been exposed to acute or long-term 100 mg/kg
CBD exhibited an anxiolytic-like LD phenotype. On the other
hand, the anxiolytic effect of long-term CBD (1 and 100 mg/kg) in
the OF in WT mice was not present in Nrg1 TM HET mice,
suggesting that the effects of CBD on anxiety-related behaviour
are dependent on an intact Nrg1 transmembrane domain. The fact
that anxiolytic-like effects of CBD were only observed in the OF
test reflects the importance of the choice of anxiety test used to
explore the effects of pharmacological and genetic manipulations,
as reported previously in Nrg1 TM HET [25,35] and CBD-treated
C57BL/6JArc mice [14].
Social interaction. There were no pronounced baseline
social interaction differences between Nrg1 TM HET and WT
mice, in accordance with our previous observations in adult mice
[29,32]. Interestingly, long-term CBD robustly increased the total
active social interaction time and specific social behaviours such as
nosing and anogenital sniffing in Nrg1 TM HET but not WT mice, at a
dose (50 mg/kg) which had no concomitant effect on locomotor
activity (data not shown). This selective increase in social
behaviour in Nrg1 TM HET mice suggests that Nrg1 mutation
renders mice more responsive to the facilitatory effects of long-
term CBD on social behaviour. Indeed, while CBD has previously
been reported to have no outright effect on social interaction in
wild type mouse and rat strains [14,36] it reverses pharmacological
deficits in social interaction induced by compounds such as THC
[36,37]. Together, these data suggest that the potential for CBD to
improve social function may be unmasked by the Nrg1 mutation.
Sensorimotor gating. Acute CBD (100 mg/kg) selectively
increased both PPI and the startle response in Nrg1 TM HET
mice. While it is possible that the enhanced PPI may be due to the
Figure 5. Concentration (ng/ml) of CBD in whole blood 2 days
after the last treatment. Data represent means+S.E.M.
doi:10.1371/journal.pone.0034129.g005
Figure 6. Representative autoradiograms showing [
3H]ketanserin (5-HT2A receptors) and [
3H]muscimol (GABAA receptors) binding
in specific brain regions. Abbreviations: Cg: anterior cingulate cortex; CPu: caudate putamen; HPC: hippocampus; LSD: dorsolateral septum; PrL:
prelimbic cortex; RSG: granular retrosplenial cortex; SN: substantia nigra; Thal: thalamus.
doi:10.1371/journal.pone.0034129.g006
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shown that baseline and pharmacologically-induced alterations in
PPI are able to be dissociated from startle pulse- or prepulse-
elicited reactivity [38,39]. Indeed, acute (1, 5 and 50 mg/kg) and
chronic (1 mg/kg) CBD enhanced PPI in male C57BL/6JArc
mice without concomitant alteration in startle reactivity [14],
while acute (1–15 mg/kg) CBD had no effect on PPI in male Swiss
mice but increased the startle response [15]. This suggests a dose-
and strain-dependent effect of CBD on ASR. However, additional
research has to investigate this phenomenon further, as a recent
study in rats suggests ASR-suppressing properties for CBD [40].
Interestingly, PPI was decreased in vehicle-treated Nrg1 TM HET
mice only when tested after cessation of CBD treatment, reflecting
the elusive and protocol-dependent nature of a definitive baseline
PPI phenotype in Nrg1 TM HET mice [26,41,42].
Pharmacokinetics of CBD
Accumulation of CBD in blood in a dose-dependent manner
was reflected by comparable CBD levels after treatment was
withheld for 48 h in both Nrg1 TM HET and WT mice. Recent
Table 3. Specific [
3H]ketanserin, [
3H]muscimol, [
3H]CP 55,940, [
3H]WAY 100.635 and [
3H]MK-801 binding in different brain regions.
Region WT Nrg1 TM HET
Vehicle CBD 1 CBD 50 CBD 100 Vehicle CBD 1 CBD 50 CBD 100
[
3H]ketanserin (5-HT2A receptors)
Prelimbic cortex 30.462.4 30.960.3 30.361.9 31.361.4 31.460.9 30.160.8 31.361.1 31.061.0
Cingulate cortex 30.660.9 30.660.7 30.561.2 30.260.8 30.761.0 31.460.5 30.060.5 30.160.3
Caudate putamen 28.760.8 28.461.4 29.062.5 27.960.8 28.161.0 29.361.0 27.860.8 27.860.8
Hippocampus 25.860.5 25.460.5 25.560.8 25.360.7 25.361.1 26.160.3 25.261.0 25.060.9
Substantia nigra 34.660.9 33.461.8 31.361.0# 32.062.6 32.361.1* 34.160.9 33.062.0 32.460.7
[
3H]muscimol (GABAA receptors)
Prelimbic cortex 21.860.1 21.760.8 21.961.3 21.561.5 20.860.9 21.361.1 22.261.1 21.161.9
Cingulate cortex 22.760.3 23.061.3 23.361.4 22.460.9 22.361.0 22.760.6 23.361.3 22.362.1
Caudate putamen 20.160.3 20.260.7 20.260.8 19.860.6 19.760.6 20.060.4 20.460.6 19.761.2
Dorsolateral septum 19.760.8 19.560.7 19.460.9 19.761.0 19.360.5 19.060.8 19.260.7 19.461.2
Retrosplenial granular cortex 20.560.8 20.560.6 20.260.7 20.560.8 19.960.3 20.460.7 21.360.6## 20.360.5
CA1 22.360.9 22.261.2 21.661.5 22.061.2 21.661.0 21.661.0 22.461.2 21.961.2
Dentate gyrus 22.360.9 22.461.1 22.061.5 22.561.3 22.161.5 22.160.7 23.061.4 22.661.3
Thalamus 23.461.1 23.460.9 23.461.6 23.261.1 22.761.1 22.860.7 24.161.5 23.061.1
[
3H]CP 55,940 (CB1 receptors)
Cingulate cortex 27.060.6 26.460.5 26.861.0 26.660.6 26.460.4 26.860.4 27.261.0 27.060.7
Caudate putamen 26.360.3 26.460.7 26.660.6 26.160.8 26.360.4 26.860.4 26.660.3 26.660.3
Dorsolateral septum 25.560.9 25.361.1 25.361.1 25.161.5 25.460.5 25.461.2 25.760.9 25.860.6
Ventrolateral septum 25.461.1 25.461.4 26.661.3 25.761.1 26.461.0 25.561.5 25.862.1 25.261.1
Hippocampus 26.360.5 26.060.6 26.160.5 25.961.2 26.260.9 26.260.6 26.761.0 26.660.7
Substantia nigra 105.669.7 101.065.2 96.468.9 97.969.6 106.065.7 102.569.2 102.663.2 107.6612.7
[
3H]WAY 100,635 (5-HT1A receptors)
Cingulate cortex 25.961.8 25.561.0 26.160.7 26.361.0 26.160.8 25.860.9 25.661.2 25.560.7
Hippocampus 85.369.7 86.565.7 85.266.7 84.5610.6 86.762.8 88.465.2 86.364.7 83.164.6
Lateral septum 31.362.1 32.161.7 32.360.8 31.362.3 32.361.4 31.961.1 31.461.4 31.660.6
Retrosplenial granular cortex 30.163.1 28.661.5 28.861.5 29.862.4 31.162.4 30.060.7 30.561.8 29.362.0
Nucleus of the vertical limb of the diagonal
band
32.363.0 33.262.0 33.361.1 31.462.7 32.062.6 34.161.3 33.661.8 32.862.3
[
3H]MK-801 (NMDA receptors)
Cingulate cortex 36.960.9 37.861.6 38.161.7 37.660.7 37.560.5 38.660.7 38.361.0 38.160.8
Caudate putamen 31.461.0 32.161.1 32.161.3 32.460.8 32.260.4 32.260.5 32.561.0 31.861.2
Hippocampus 109.962.3 111.664.6 111.965.1 111.262.5 110.462.3 113.063.9 114.864.9 111.763.6
Dorsolateral septum 34.062.2 33.961.3 35.562.0 34.062.1 35.560.4 36.061.1 33.662.5 33.261.1
Retrosplenial granular cortex 32.461.4 33.261.5 33.661.6 32.661.0 32.860.4 33.261.0 34.561.1 33.561.0
[
3H]ketanserin, [
3H]muscimol, [
3H]CP 55,940, [
3H]WAY 100,635 and [
3H]MK-801 binding 48 h after the last of 21 daily injections of CBD (1, 50 or 100 mg/kg) (on WH day).
Data represent mean binding density nCi/mg tissue (6 S.E.M.). Significant one-way ANOVA (split by corresponding factor) results are shown:
*P,0.05 (vs. WT receiving corresponding treatment),
#P,0.05,
##P,0.01 (vs. vehicle of corresponding genotype).
doi:10.1371/journal.pone.0034129.t003
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i.p. to mice is undetectable in brain and plasma after 24 h using
tandem liquid chromatography mass spectrometry [43]. However,
our method detected CBD in whole blood 48 h after the last i.p.
injection suggesting that CBD accrues in the body with repeated
exposure. This effect of repeated administration might be due to
CBD’s hydrophobicity and would be similar to the characteristics
of THC that is retained in lipid rich tissues [44,45]. It is possible
that residual CBD affected the behavioural performance of test
mice during the WH day. However, the lack of difference between
residual CBD levels suggests that the behavioural and receptor
binding differences between genotypes are not due to simple
differences in CBD blood concentration.
CBD alters 5-HT2A and GABAA receptor binding in a
genotype-specific manner
Nrg1 TM HET mice displayed a baseline decrease in 5-HT2A
receptor binding in the substantia nigra. CBD (50 mg/kg)
selectively reduced binding of 5-HT2A receptors in the substantia
nigra in WT mice and increased binding of GABAA receptors in
the retrosplenial granular cortex in mutant mice. These changes in
5-HT2A and GABAA occur in areas relevant to both the
behavioural changes we have observed and to the pathophysiology
of schizophrenia. Midbrain 5-HT2 receptors regulate striatal
dopaminergic transmission [46,47]. Therefore, reduced 5-HT2A
receptor density might be related to the hyperactivity that occurs
in Nrg1 TM HET mice. On the other hand, increased 5-HT2A
binding in the cortex of adult Nrg1 TM HET mice [48] suggests
that changes in these receptors in response to Nrg1 mutation may
occur in a region- and thus functionally specific manner. The
GABAA binding increase in the granular retrosplenial cortex of
mutant mice treated with CBD (50 mg/kg) occurred in the
absence of baseline binding differences. Since the retrosplenial
cortex mediates emotional responsivity and processing of emo-
tional salience [49,50], it is tempting to speculate that the selective
increase in social interaction by the same dose of CBD in mutant
mice is related to the change in GABAA binding. Indeed, GABAA
agonists exert anxiolytic-like effects in the social interaction test
[51].
Brains were collected from mice that had not received CBD for
48 h. It is possible that the binding changes we observed are
related to a withdrawal-like state induced by withholding CBD
treatment for 48 h, rather than to changes induced by the long-
term treatment itself. However, the presence of CBD in blood at
the same time as the collection of brain tissue and the absence of
any withdrawal symptoms in the test cohorts suggest that
withdrawal effects are unlikely.
It is tempting to speculate on mechanisms underlying the
unmasking of certain effects of CBD, such as anxiolytic-like effects
in Nrg1 mutant mice, since our data would suggest that the normal
functioning of Nrg1 might suppress some effects of CBD. For
example, Nrg1 mutation might enhance the responsiveness of
targets of CBD suggested to be involved in modulating anxiety,
such as the 5-HT1A receptor [12,52]. We did not observe
increased 5-HT1A receptor binding in our mutants; nevertheless
this does not rule out enhanced signal transduction from this
receptor that might be related to altered Nrg1 function. CBD
might also modify behaviour via altering endocannabinoid tone,
e.g. via inhibition of the anandamide hydrolysis enzyme fatty acid
amide hydrolase [24]. Given that inhibition of this enzyme has
documented anxiolytic effects [53], it would be worth investigating
common signalling pathways between Nrg1 and the endocanna-
binoid system.
In conclusion, we present the novel findings that CBD alters
specific aspects of the behavioural phenotype and brain receptor
binding density in Nrg1 TM HET mice. CBD did not reverse
several of the schizophrenia-related behavioural features of mutant
mice, namely hyperactivity, reduced PPI and reduced 5-HT2A
receptor density, although unlike those treated with vehicle,
mutants treated with higher doses of CBD failed to express
significant hyperactivity. CBD selectively enhanced social behav-
iour, prepulse inhibition, and retrosplenial GABAA binding in
Nrg1 TM HET mice, supporting its potential therapeutic value in
treating specific symptoms of schizophrenia. It appears that
mutation in Nrg1 unmasks this behavioural effect of CBD, whereas
intact Nrg1 is crucial for its anxiolytic effects. Future research has
to investigate the effectiveness of long-term treatment with
established antipsychotic drugs in this animal model to enable
the evaluation of the current findings for schizophrenia therapy.
Materials and Methods
Animals
Male heterozygous Nrg1
+/2 (Nrg1 TM HET) and wild type-like
control Nrg1
+/+ (WT) littermates [25] aged 2163 weeks were used
as males exhibit a stronger sensitivity to cannabinoids than females
[29,32]. Standard social interaction opponents were age-matched
male A/JArc mice (Animal Resources Centre, Canning Vale,
Australia). Mice were pair-housed with limited environmental
enrichment [mouse igloo (Bioserv, Frenchtown, USA) and a metal
ring in the cage lid] under a 12:12 h light:dark schedule. Food and
water were available ad libitum. Research and animal care
procedures were approved by the University of New South Wales
Animal Care and Ethics Committee in accordance with the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes (ACEC approval number: 08/28A).
Drug treatment
CBD (THC Pharm GmbH, Frankfurt, Germany) was suspend-
ed in a 1:1:18 mixture of ethanol:Tween 80H:saline. Mice received
21 consecutive daily intraperitoneal (i.p.) injections of vehicle
(1:1:18 ethanol:Tween 80H:saline mixture) or CBD (1, 50 or
100 mg/kg) at a volume of 10 ml/kg as published previously [14].
Behavioural testing
Treatment injections commenced 30 min after the start of the
light cycle. Mice were behaviourally tested 30–45 min post
injection on the first day of treatment (‘‘acute’’ group) and on
intermittent days throughout repeated treatment (‘‘long-term’’
group), and after two days after the final dose of CBD treatment
[‘‘treatment withheld (WH day)’’ group] (Table 4). On behav-
ioural testing days injections were staggered within the light cycle
to standardise intervals between injection and testing [i.e. as
groups of test mice (maximum of four mice at a time) were run
consecutively, injections were administered the requisite number
of minutes prior to testing to ensure consistent intervals between
treatment and testing]. Mice were returned to the home cage
following injection and behavioural testing. Environmental odours
were removed from test apparatus between trials with 70%
ethanol. The test order was based on an earlier study [14].
Light–dark test (LD). Mice were placed into the opening of
a dark box insert in an open field (OF) activity chamber
(41641 cm; Tru-Scan Photo Beam Activity System: Coulbourn
Instruments, Whitehall, USA) for 10 min. Horizontal activity
(distance travelled) for both light (,70 lx) and dark chambers
(,5 lx) was measured by the Tru-Scan system and ANY-maze
TM
video tracking software (Stoelting Co., Wood Dale, USA; light
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subtraction of time in the light chamber (measured by ANY-maze)
from the total test time. The ratio of distance travelled in the light
compartment to total distance travelled (distance ratio) and time
spent in the light compartment were taken as measures of anxiety.
Spontaneous locomotor activity. Locomotor activity was
measured in the OF chamber for 10 min. Distance travelled and
vertical activity (rearing) in central and peripheral zones (centre
coordinates 7.6 cm67.6 cm from the periphery) were measured
by Tru-Scan and ANY-maze
TM software. The ratio of central to
total distance travelled (distance ratio) and time spent in the centre
were taken as measures of anxiety [54].
Novel object recognition test (NORT). The distinction
between familiar and unfamiliar objects is an index of recognition
memory [55,56]. Mice were habituated to the empty NORT
apparatus (grey perspex arena; 35635630 cm) for 5 min twice
daily for 2 days. The following day, mice were habituated twice to
the test procedure (i.e. exposure to identical objects placed in
opposite corners). The next day, mice were placed in the arena for
10 min, which contained two novel identical objects, and allowed
to explore freely (test trial 1). In test trial 2, 60 min later, the arena
contained one copy of these objects (familiar object) and one novel
object in the same positions as in test trial 1. Object exploration
was scored for 5 min by the behaviours nosing (when the mouse
directed its nose to an object at a distance of #1 cm) and rearing on
the object. Data from NORT are not reported since the
performance of WT mice at the novel object was not
significantly different from chance (i.e. no indication of successful
learning of objects).
Social interaction (SI). SI between rodent pairs is used to
measure anxiety-like behaviours [57]. Furthermore, reduction in
SI models aspects of social withdrawal, which is also observed in
schizophrenia patients [58]. Test mice and untreated, weight-
matched (i.e. A/J body weight,test mice body weight) standard
opponents were placed in opposite corners of the arena, which was
used for NORT testing. Frequency and duration of the active
socio-positive behaviours nosing [i.e. test mouse sniffs at the
opponent’s body, which is in close proximity to the test mouse
(,1 cm)], anogenital sniffing, allogrooming, following and climbing over/
under were scored for 10 min. Distance travelled was measured by
ANY-maze
TM.
Prepulse inhibition (PPI). PPI, an operational measure of
sensorimotor gating impaired in schizophrenia patients [59], is the
attenuation of the startle response by a non-startling stimulus
(prepulse) presented before the startling stimulus (pulse). Startle
reactivity was measured for 200 ms post pulse onset using SR-LAB
startle chambers (San Diego Instruments, San Diego, USA). The
PPI test consisted of 5 min acclimatisation to 70 dB background
noise, followed by 105 trials in a pseudorandom order as published
previously [41]: 5670 dB trials (background); 5680 dB trials;
56100 dB trials; 156120 dB trials (startle) and 5 sets of 15 trials
comprising a prepulse of either 74, 82 or 86 dB presented 32, 64,
128, 256 or 512 ms (variable interstimulus interval; ISI) prior to a
startling pulse of 120 dB (PPI response). The intertrial interval
varied randomly from 10–20 s. Acoustic startle response (ASR)
was calculated as the mean amplitude to the middle 5 startle trials
to eliminate habituation effects [60]. Percentage PPI (% PPI) was
calculated as [(mean startle response – PPI response)/mean startle
response]6100. % PPI was averaged across ISIs.
Detection and quantification of CBD in whole blood
samples
Trunk blood was collected in EDTA-coated tubes immediately
after PPI testing on WH day. CBD concentration was measured as
described previously [44] with modifications for CBD analysis
[61,62]. 50 ml of D3-CBD (0.25 mg/L; PM Separations, Capa-
laba, Australia) internal standard solution was added to 0.5 ml
trunk blood. Acetate buffer was added (pH 4.0) and CBD
extracted with 1-chloro-butane solvent. Following complete drying
under nitrogen, samples underwent derivatisation of the polar
functional groups (COOH, OH) with bis(trimethylsilyl)trifluroa-
cetamide. Quantification (1.25 ng/ml limit of quantification) of
the derivatised extract was performed by gas chromatography-
mass spectrometry (GC-MS) (Shimadzu 2010 Plus system:
Shimadzu Scientific Instruments, Rydalmere, Australia).
Receptor autoradiography
Brains from a subset of sacrificed mice (n=4–5 per factor;
selected randomly) were dissected 48 h after the last CBD
injection, snap frozen and stored at 280uC. Coronal sections
(14 mm) were cut and thaw-mounted onto slides. Specific receptors
were chosen to investigate the effects of CBD treatment on the
endocannabinoid system (i.e. CB1) and to determine the impact of
CBD on a selection of central neurotransmitter systems relevant to
schizophrenia (i.e. NMDA, 5-HT1A, 5-HT2A and GABAA). For
analysis, brain regions with relevance to schizophrenia and the
endocannabinoid system were chosen in particular.
Table 4. Test biography of mice.
Test/Treatment Day Test
1 Light-dark test (LD), open field (OF), prepulse inhibition (PPI)
13 OF
14 Novel object recognition test (NORT) habituation trials 1–2
15 LD, NORT habituation trial 3
16 NORT habituation trials 4–5
17 NORT test trials 1–2
19 Social interaction
21 PPI
WH OF, LD, PPI
126 mice were injected with either vehicle or CBD (1, 50 or 100 mg/kg body weight) once daily from test day 1–21 (n=14–17). Animals were tested again in OF,L Da n d
PPI 48 h after the completion of the chronic CBD administration (WH day=test day 23).
doi:10.1371/journal.pone.0034129.t004
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were incubated for in 50 mM Tris-HCl buffer (pH 7.4)
containing 5% bovine serum albumin (30 min) then in the same
buffer containing 10 nM [
3H]CP-55,940 (168 Ci/mmol; Perkin
Elmer, Boston, USA) in the presence (non-specific binding) or
absence (total binding) of 10 mM CP 55,940 [63].
For 5-HT1A receptors, sections were incubated in 50 nM Tris-
HCl buffer (30 min) then in the same buffer containing 5 nM [
3H]
WAY-100635 (83 Ci/mmol; Perkin Elmer) and 10 M pargyline in
the presence (non-specific binding) or absence (total binding) of
10 mM 5-HT (150 min) [64].
For 5-HT2A receptors, sections were incubated in 170 mM
Tris-HCl buffer (15 min) then in the same buffer containing 4 nM
[
3H]ketanserin (88 Ci/mmol; Perkin Elmer) in the presence (non-
specific binding) or absence (total binding) of 2 mM spiperone
(120 min) [65].
For NMDA receptors, sections were incubated in 30 mM
HEPES buffer (pH 7.5) containing 100 mM glycine, 100 mM
glutamate, 1 mM EDTA and 20 nM [
3H]MK-801 (17.1 Ci/
mmol; Perkin Elmer) in the presence (non-specific binding) or
absence (total binding) of 20 mM MK-801 (2.5 h) [66].
For GABAA receptors, sections were incubated in 50 mM Tris-
HCl buffer (pH 7.0) (365 min) then in the same buffer containing
3n M[
3H]muscimol (29.5 Ci/mmol) in the presence (non-specific
binding) or absence (total binding) of 100 mM GABA (40 min)
[67].
All sections were washed in ice-cold buffer, dipped in distilled
water and air dried.
Quantification. Slides were exposed to Kodak BioMax MR
film. Developed films were analysed using a computer-assisted
image analysis system, Multi-Analyst, connected to a GS-690
Imaging Densitometer (Bio-Rad, Hercules, USA). Binding
quantification was performed by measuring the average density
in brain regions identified using a mouse brain atlas [68] in 2–3
adjacent sections and comparing the values against
autoradiographic standards (Amersham: GE Healthcare,
Buckinghamshire, UK).
Statistical analysis
Behavioural measures and binding density were analysed with
two-way analysis of variance (ANOVA) (between-subjects factors:
‘treatment’ and ‘genotype’) to distinguish between acute (day 1),
long-term (days 13–21), and treatment withheld (day 23) effects.
Repeated measures (RM) three-way ANOVAs were used for
NORT [within-subjects factor: ‘object’ (novel or familiar)] and PPI
(within-subjects factor: ‘prepulse intensity’). Initial ANOVAs were
followed by two- or one-way ANOVAs split by the corresponding
factor(s) if appropriate as published previously [29–32]. Differ-
ences between CBD doses were determined with Dunnett’s post-
hoc test whereas body weight was compared using an unpaired t-
test. Data are presented as means 6 standard error of the mean
(S.E.M.). Main effects were regarded as statistically significant
when P,0.05. A total of 126 mice were tested (n=14–17).
Degrees of freedom, F-values and P-values are shown for three-
and two-way ANOVAs (* versus WT receiving corresponding
treatment; # versus vehicle of corresponding genotype) are
presented. In case malfunction of software or test equipment
occurred, data were excluded, resulting in altered degrees of
freedom for some analyses. Analysis was performed using SPSS
17.0.
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